Precision AQ
Andrew DymonAssociate Director
Andrew Dymon is an Associate Director at Precision AQ where he has spent the last four years providing strategic investor relations counsel to private and public biotech companies across the evolving biotechnology landscape. Andrew’s deep analytical skills and attention to detail have enabled him to act as an advisor to companies through a variety of pivotal inflection points, including data readouts, key financings, product approvals, M&A, IPOs, and more.
Insights from Andrew Dymon
Commercialization & Access | White Paper
Wall Street Perspective on Radiopharmaceuticals